市场调查报告书

全球癌症免疫治疗装的药外包市场规模,占有率,趋势分析:药物,各类服务,各癌症(肺癌,乳癌,大肠癌,黑色素瘤,前列腺癌,胰脏癌),各市场区隔预测

Cancer Immunotherapy Drug Discovery Outsourcing Market Analysis Report By Drug, By Service, By Cancer Type (Lung, Breast, Colorectal, Melanoma, Prostate, Pancreatic), And Segment Forecasts, 2018 - 2025

出版商 Grand View Research, Inc. 商品编码 785955
出版日期 内容资讯 英文 95 Pages
商品交期: 2-3个工作天内
价格
全球癌症免疫治疗装的药外包市场规模,占有率,趋势分析:药物,各类服务,各癌症(肺癌,乳癌,大肠癌,黑色素瘤,前列腺癌,胰脏癌),各市场区隔预测 Cancer Immunotherapy Drug Discovery Outsourcing Market Analysis Report By Drug, By Service, By Cancer Type (Lung, Breast, Colorectal, Melanoma, Prostate, Pancreatic), And Segment Forecasts, 2018 - 2025
出版日期: 2018年11月30日内容资讯: 英文 95 Pages
简介

本报告提供全球癌症免疫治疗装的药外包市场相关调查,汇整市场趋势与各市场区隔趋势,各地区预测,加入此市场的主要企业的简介相关资讯。

第1章 调查方法与范围

第2章 摘要整理

第3章 市场变动,趋势,范围

  • 市场区隔

第4章 产业预测

  • 市场变动分析
  • 推动市场的要素分析
  • 阻碍市场的要素分析
  • 波特五力分析

第5章 药物类别商务分析

  • 趋势分析
  • 单株抗体
  • 免疫调节药物
  • 癌症疫苗与溶瘤治疗
  • 其他

第6章 各类服务商务分析

  • 趋势分析
  • 标的鉴定和验证
  • 领导筛检和特性化
  • 细胞化验分析

第7章 各癌症商务分析

  • 趋势分析
  • 肺癌
  • 乳癌
  • 大肠癌
  • 黑色素瘤
  • 前列腺癌
  • 头颈癌
  • 卵巢癌
  • 胰脏癌

第8章 各地区预测与趋势分析

  • 市场占有率
  • 北美
  • 欧洲
  • 亚太地区
  • 南美
  • 中东·非洲

第9章 企业简介

  • 策略架构
  • Explicit Immuno-Oncology
  • Aquila Biomedical
  • Horizon Discovery Group plc
  • Crown Bioscience Inc.
  • Promega Corporation
  • HD Biosciences Co. Ltd.
  • BPS Biosciences Inc.
  • Gen script Biotech Corporation
  • Celentyx Ltd.
  • ImmuneXperts SA
  • Personalis
  • STC Biologics
  • Molecular Imaging Inc.
  • Covance, Inc.
目录
Product Code: GVR-2-68038-646-2

The global cancer immunotherapy drug discovery outsourcing market size is projected to reach USD 1.7Billion by 2025, according to a new report by Grand View Research, Inc., rising at a CAGR of 13.5% during the forecast period. Increasing prevalence of cancer and rising mortality associated with cancer, along with growing development in the field of cancer immunotherapy, are anticipated to stimulate the growth of the market.

In order to maintain pace with increasing competition in the cancer therapeutics industry, pharmaceutical companies spend 2.5% more than other high tech industries in the in-house R&D. Hence, they are swiftly shifting towards outsourcing of drug discovery in order to achieve lower in-house R&D costs.

Additionally, favorable tax credit allows pharmaceutical companies to appropriately plan their global projects with a reputed CRO and therefore, receive benefits and reduce problems associated with taxation authorities or other bodies administering such incentive programs.

Several new molecules for cancer immunotherapy and new immunotherapeutic options, such as tumor infiltrating lymphocytes, check point inhibitors immunomodulators, and CAR-T cell therapy, have been introduced. Some are in the pipeline and are being tested for their ability to provide better cancer treatment

Further key findings from the study suggest:

Monoclonal antibodies emerged as the largest segment in 2017 because of increasing regulatory approvals and higher efficacy

Target identification and validation accounted for the largest share in the global market owing to higher costs incurred and increased investments in new drug development

North America dominated the market with the largest share in 2017. Rising incidence of cancer and increasing demand for novel technologies are facilitating the dominance of the region during the forecast period

Some of the key players are Covance, Inc.; Explicyte; Aquila BioMedical; Horizon Discovery Group PLC; Crown Bioscience, Inc.; Promega Corporation; HD Biosciences Co., Ltd.; BPS Bioscience, Inc.; Genscript Biotech Corporation; DiscoverX Corporation; Celentyx Ltd.; ImmunXperts SA; Personalis, Inc.; STC Biologics; and Molecular Imaging, Inc. dominated the cancer immunotherapy drug discovery outsourcing market.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Research Methodology
  • 1.2 Research Scope and Assumptions

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Segmentation

Chapter 4 Industry Outlook

  • 4.1 Market Variable Analysis
    • 4.1.1 Increasing in-house R & D costs
    • 4.1.2 Increasing adoption of advanced technologies
    • 4.1.3 Mergers and acquisitions
    • 4.1.4 Tax credit
  • 4.2 Market Restraint Analysis
    • 4.2.1 Quality issues involved with drug discovery cro services
    • 4.2.2 Intellectual property right issues
  • 4.3 Porter's Five Forces Analysis

Chapter 5 Drug Type Business Analysis

  • 5.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: Drug Movement Analysis
  • 5.2 Monoclonal Antibodies
    • 5.2.1 Monoclonal antibodies market estimates and forecast, 2014 - 2025
  • 5.3 Immunomodulators
    • 5.3.1 Immunomodulators market estimates and forecast, 2014 - 2025
  • 5.4 Cancer Vaccines and Oncolytic Therapies
    • 5.4.1 Cancer vaccines and oncolytic therapies market estimates and forecast, 2014 - 2025
  • 5.5 Others
    • 5.5.1 Others market estimates and forecast, 2014 - 2025

Chapter 6 Service Business Analysis

  • 6.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: service Movement Analysis
  • 6.2 Target Identification and Validation
    • 6.2.1 Target identification and validation market estimates and forecast, 2014 - 2025
  • 6.3 Lead screening and Characterization
    • 6.3.1 Lead screening and characterization market estimates and forecast, 2014 - 2025
  • 6.4 Cell based Assays
    • 6.4.1 Cell based assays market estimates and forecast, 2014 - 2025

Chapter 7 Cancer Business Analysis

  • 7.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: Cancer Movement Analysis
  • 7.2 Lung Cancer
    • 7.2.1 Lung cancer market estimates and forecast, 2014 - 2025
  • 7.3 Breast Cancer
    • 7.3.1 Breast cancer market estimates and forecast, 2014 - 2025
  • 7.4 Colorectal Cancer
    • 7.4.1 Colorectal cancer market estimates and forecast, 2014 - 2025
  • 7.5 Melanoma
    • 7.5.1 Melanoma market estimates and forecast, 2014 - 2025
  • 7.6 Prostate Cancer
    • 7.6.1 Prostate cancer market estimates and forecast, 2014 - 2025
  • 7.7 Head and Neck Cancer
    • 7.7.1 Head and neck cancer market estimates and forecast, 2014 - 2025
  • 7.8 Ovarian Cancer
    • 7.8.1 Ovarian cancer market estimates and forecast, 2014 - 2025
  • 7.9 Pancreatic Cancer
    • 7.9.1 Pancreatic cancer market estimates and forecast, 2014 - 2025

Chapter 8 Regional Business Analysis

  • 8.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: Regional Movement Analysis
  • 8.2 North America
    • 8.2.1 North America market estimates and forecast, 2014 - 2025
    • 8.2.2 U.S.
      • 8.2.2.1 U.S. market estimates and forecast, 2014 - 2025
    • 8.2.3 Canada
      • 8.2.3.1 Canada market estimates and forecast, 2014 - 2025
  • 8.3 Europe
    • 8.3.1 Europe market estimates and forecast, 2014 - 2025
    • 8.3.2 Germany
      • 8.3.2.1 Germany market estimates and forecast, 2014 - 2025
    • 8.3.3 UK
      • 8.3.3.1 UK market estimates and forecast, 2014 - 2025
  • 8.4 Asia Pacific
    • 8.4.1 Asia Pacific market estimates and forecast, 2014 - 2025
    • 8.4.2 India
      • 8.4.2.1 India market estimates and forecast, 2014 - 2025
    • 8.4.3 China
      • 8.4.3.1 China market estimates and forecast, 2014 - 2025
  • 8.5 Latin America
    • 8.5.1 Latin america market estimates and forecast, 2014 - 2025
    • 8.5.2 Brazil
      • 8.5.2.1 Brazil market estimates and forecast, 2014 - 2025
    • 8.5.3 Mexico
      • 8.5.3.1 Mexico market estimates and forecast, 2014 - 2025
  • 8.6 Middle East & Africa
    • 8.6.1 Middle east and africa market estimates and forecast, 2014 - 2025
    • 8.6.2 South Africa
      • 8.6.2.1 South Africa market estimates and forecast, 2014 - 2025

Chapter 9 Company Profile

  • 9.1 Strategy Framework
  • 9.2 Explicit Immuno-Oncology
    • 9.2.1 Company overview
    • 9.2.2 SWOT analysis
    • 9.2.3 Product benchmarking
    • 9.2.4 Strategic initiatives
  • 9.3 Aquila Biomedical
    • 9.3.1 Company overview
    • 9.3.2 SWOT analysis
    • 9.3.3 Product benchmarking
    • 9.3.4 Strategic initiatives
  • 9.4 Horizon Discovery Group plc
    • 9.4.1 Company overview
    • 9.4.2 Financial performance
    • 9.4.3 Product benchmarking
    • 9.4.4 Strategic initiatives
    • 9.4.5 SWOT analysis
  • 9.5 Crown Bioscience Inc.
    • 9.5.1 Company overview
    • 9.5.2 SWOT analysis
    • 9.5.3 Product benchmarking
    • 9.5.4 Strategic initiatives
  • 9.6 Promega Corporation
    • 9.6.1 Company overview
    • 9.6.2 SWOT analysis
    • 9.6.3 Product benchmarking
    • 9.6.4 Strategic initiatives
  • 9.7 HD Biosciences Co. Ltd.
    • 9.7.1 Company overview
    • 9.7.2 SWOT analysis
    • 9.7.3 Product benchmarking
    • 9.7.4 Strategic initiatives
  • 9.8 BPS Biosciences Inc.
    • 9.8.1 Company overview
    • 9.8.2 SWOT analysis
    • 9.8.3 Product benchmarking
    • 9.8.4 Strategic initiatives
  • 9.9 Gen script Biotech Corporation
    • 9.9.1 Company overview
    • 9.9.2 Financial performance
    • 9.9.3 Product benchmarking
    • 9.9.4 Strategic initiatives
    • 9.9.5 SWOT analysis
  • 9.10 Celentyx Ltd.
    • 9.10.1 Company overview
    • 9.10.2 SWOT analysis
    • 9.10.3 Product benchmarking
    • 9.10.4 Strategic initiatives
  • 9.11 ImmuneXperts SA
    • 9.11.1 Company overview
    • 9.11.2 SWOT analysis
    • 9.11.3 Product benchmarking
    • 9.11.4 Strategic initiatives
  • 9.12 Personalis
    • 9.12.1 Company overview
    • 9.12.2 Product benchmarking
    • 9.12.3 Strategic initiatives
    • 9.12.4 SWOT analysis
  • 9.13 STC Biologics
    • 9.13.1 Company overview
    • 9.13.2 SWOT analysis
    • 9.13.3 Product benchmarking
    • 9.13.4 Strategic initiatives
  • 9.14 Molecular Imaging Inc. (MI Bioresearch Inc.)
    • 9.14.1 Company overview
    • 9.14.2 SWOT analysis
    • 9.14.3 Product benchmarking
    • 9.14.4 Strategic initiatives
  • 9.15 Covance, Inc.
    • 9.15.1 Company overview
    • 9.15.2 Financial performance
    • 9.15.3 Product benchmarking
    • 9.15.4 Strategic initiatives
    • 9.15.5 Swot analysis

List of Tables

  • TABLE 1 List of Strategic Partnerships
  • TABLE 2 Gap analysis: Cancer immunotherapy drug discovery outsourcing services
  • TABLE 3 North America cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 4 North America cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
  • TABLE 5 North America cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
  • TABLE 6 U.S. cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 7 U.S. cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
  • TABLE 8 U.S. cancer immunotherapy drug discovery outsourcing market outsourcing market, by cancer type, 2014 - 2025 (USD Million)
  • TABLE 9 Canada cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 10 Canada cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
  • TABLE 11 Canada cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
  • TABLE 12 Europe cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 13 Europe cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
  • TABLE 14 Europe cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
  • TABLE 15 U.K. cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 16 U.K. cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
  • TABLE 17 U.K. cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
  • TABLE 18 Germany cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 19 Germany cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
  • TABLE 20 Germany cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
  • TABLE 21 Asia Pacific cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 22 Asia Pacific cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
  • TABLE 23 Asia Pacific cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
  • TABLE 24 China cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 25 China cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
  • TABLE 26 China cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
  • TABLE 27 India cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 28 India cancer immunotherapy drug discovery outsourcing market, by service Type, 2014 - 2025 (USD Million)
  • TABLE 29 India cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
  • TABLE 30 Latin America cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 31 Latin America cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
  • TABLE 32 Latin America cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
  • TABLE 33 Brazil cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 34 Brazil cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
  • TABLE 35 Brazil cancer immunotherapy drug discovery outsourcing market, by cancer type , 2014 - 2025 (USD Million)
  • TABLE 36 Mexico cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 37 Mexico cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
  • TABLE 38 Mexico cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
  • TABLE 39 MEA cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 40 MEA cancer immunotherapy drug discovery outsourcing market, by service Type, 2014 - 2025 (USD Million)
  • TABLE 41 MEA cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
  • TABLE 42 South Africa cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 43 South Africa cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
  • TABLE 44 South Africa cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Cancer immunotherapy drug discovery outsourcing market snapshot
  • FIG. 2 Cancer immunotherapy drug discovery outsourcing market segmentation
  • FIG. 3 Cancer immunotherapy drug discovery outsourcing market driver impact
  • FIG. 4 Cancer immunotherapy drug discovery outsourcing market restraint impact
  • FIG. 5 SWOT analysis, By Factor (political & legal economic and technological)
  • FIG. 6 Porter's five forces analysis
  • FIG. 7 Cancer immunotherapy drug discovery outsourcing market: Drug type outlook and key takeaways
  • FIG. 8 Cancer immunotherapy drug discovery outsourcing market: Drug movement analysis
  • FIG. 9 Monoclonal antibodies market estimates and forecast, 2014 - 2025
  • FIG. 10 Immunomodulators market estimates and forecast, 2014 - 2025
  • FIG. 11 Cancer vaccines and oncolytic therapies market estimates and forecast, 2014 - 2025
  • FIG. 12 Others market estimates and forecast, 2014 - 2025
  • FIG. 13 Cancer immunotherapy drug discovery outsourcing market: Service outlook and key takeaways
  • FIG. 14 Cancer immunotherapy drug discovery outsourcing market: Service movement analysis
  • FIG. 15 Target identification and validation market estimates and forecast, 2014 - 2025
  • FIG. 16 Lead screening and characterization market estimates and forecast, 2014 - 2025
  • FIG. 17 Cell based assays market estimates and forecast, 2014 - 2025
  • FIG. 18 Cancer immunotherapy drug discovery outsourcing market: Cancer outlook and key takeaways
  • FIG. 19 Cancer immunotherapy drug discovery outsourcing market: Service movement analysis
  • FIG. 20 Lung cancer market estimates and forecast, 2014 - 2025
  • FIG. 21 Breast cancer market estimates and forecast, 2014 - 2025
  • FIG. 22 Colorectal cancer market estimates and forecast, 2014 - 2025
  • FIG. 23 Melanoma market estimates and forecast, 2014 - 2025
  • FIG. 24 Prostate cancer market estimates and forecast, 2014 - 2025
  • FIG. 25 Head and neck cancer market estimates and forecast, 2014 - 2025
  • FIG. 26 Ovarian cancer market estimates and forecast, 2014 - 2025
  • FIG. 27 Pancreatic cancer market estimates and forecast, 2014 - 2025
  • FIG. 28 Cancer immunotherapy drug discovery outsourcing market: regional outlook and key takeaways
  • FIG. 29 Cancer immunotherapy drug discovery outsourcing market: Regional movement analysis
  • FIG. 30 North America
  • FIG. 31 North America market estimates and forecast, 2014 - 2025
  • FIG. 32 U.S. market estimates and forecast, 2014 - 2025
  • FIG. 33 Canada market estimates and forecast, 2014 - 2025
  • FIG. 34 Europe
  • FIG. 35 Europe market estimates and forecast, 2014 - 2025
  • FIG. 36 Germany market estimates and forecast, 2014 - 2025
  • FIG. 37 UK market estimates and forecast, 2014 - 2025
  • FIG. 38 Asia-Pacific
  • FIG. 39 Asia-Pacific market estimates and forecast, 2014 - 2025
  • FIG. 40 India market estimates and forecast, 2014 - 2025
  • FIG. 41 China market estimates and forecast, 2014 - 2025
  • FIG. 42 Latin America
  • FIG. 43 Latin America market estimates and forecast, 2014 - 2025
  • FIG. 44 Brazil market estimates and forecast, 2014 - 2025
  • FIG. 45 Mexico market estimates and forecast, 2014 - 2025
  • FIG. 46 Middle East & Africa
  • FIG. 47 Middle East and Africa market estimates and forecast, 2014 - 2025
  • FIG. 48 South Africa market estimates and forecast, 2014 - 2025
  • FIG. 49 Strategy Framework